COMBINATION OF BIFEPRUNOX AND AN ANTIPSYCHOTIC DRUG WITH D2/5-HT2A RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CNS DISORDERS

摘要

The present invention relates to (a pharmaceutical composition comprising) a combination of bifeprunox (a D2/5-HT1A receptor ligand) and at least one D2/5-HT2A receptor antagonistic ligand and pharmaceutically acceptable auxiliaries for use in the treatment of various CNS disorders, particularly psychotic disorders like schizophrenia and related psychiatric conditions, including bipolar disorder, bipolar depression, mania and atypical depression.